Chronic Heart Failure Pipeline Insight, Clinical Trials Analysis and FDA Approvals 2023 | Major Companies - Zensun (Shanghai) Sci & Tech, Cytokinetics, Shanghai Hongyitang Biopharmaceutical, and Others

DelveInsight's, "Chronic Heart Failure Pipeline Insight 2023" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Chronic Heart Failure pipeline landscape. It covers the Chronic Heart Failure pipeline drug profiles, including Chronic Heart Failure clinical trials and nonclinical stage products. It also covers the Chronic Heart Failure therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Heart Failure Pipeline Report
• DelveInsight's Chronic Heart Failure Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Chronic Heart Failure treatment.
• The leading Chronic Heart Failure Companies include Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, and others
• Promising Chronic Heart Failure Pipeline Therapies include Ferinject (ferric carboxymaltose), Bisoprolol, LCZ696, Valsartan, Enalapril, Aliskiren, Vericiguat, Dapagliflozin, Normal saline (0.9%), nesiritide, furosemide, and others
• The Chronic Heart Failure companies and academics are working to assess challenges and seek opportunities that could influence Chronic Heart Failure R&D. The Chronic Heart Failure therapies under development are focused on novel approaches to treat/improve Chronic Heart Failure.

Request a sample and discover the recent breakthroughs happening in the Chronic Heart Failure Pipeline landscape @ Chronic Heart Failure Pipeline Outlook- https://www.delveinsight.com/report-store/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Heart Failure Overview
Chronic heart failure (CHF) is a major public health problem in industrialized societies with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45-55, 2-5% between ages 65-75, and approximately 10% for patients aged 80 years or more. HF is a complex clinical syndrome characterized by the inability of the heart to provide the cardiac output needed by the organism at normal end-diastolic ventricular pressures.

Recent Developmental Activities in the Chronic Heart Failure Treatment Landscape
• In February, 2022, The American Food and Drug Administration has today approved Jardiance (empagliflozin) to lower the chance of adult patients hospitalizing for heart failure and dying from cardiovascular causes. For today's approval, a randomised, double-blind, multinational trial comparing 2,997 people who got Jardiance, 10 mg once daily, to 2,991 participants who received a placebo evaluated the drug's safety and efficacy as an addition to standard of care therapy.
• In August 2019, Zensun USA, Inc., announced that the investigation of NEUCARDIN, its Recombinant human neuregulin-1 fragment, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of Chronic Heart Failure (CHF). NEUCARDIN, the lead drug candidate from the company's cardiac therapy program, was also recently granted "priority review" for its conditional approval application in China by the National Medical Products Administration (NMPA) (formerly the CFDA).

For further information, refer to the detailed Chronic Heart Failure Drugs Launch, Chronic Heart Failure Developmental Activities, and Chronic Heart Failure News, click here for Chronic Heart Failure Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Heart Failure Emerging Drugs Profile
• Neucardin: Zensun (Shanghai) Sci & Tech
Neucardin is a. Recombinant human neuregulin-1 (Neucardin), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling, and significantly reducing death rate and readmission rate while improving the quality of life.

• Omecamtiv Mecarbil: Cytokinetics
Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator, the first of a novel class of myotropes1 designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during systole. Omecamtiv mecarbil is designed to increase the number of active actin-myosin cross bridges during each cardiac cycle and consequently augment the impaired contractility that is associated with heart failure with reduced ejection fraction (HFrEF). Preclinical research has shown that omecamtiv mecarbil increases cardiac contractility without increasing intracellular myocyte calcium concentrations or myocardial oxygen consumption.

• Rexlemestrocel-L (Revascor): Mesoblast
Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Heart Failure.

Chronic Heart Failure Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Chronic Heart Failure. The companies which have their Chronic Heart Failure drug candidates in the most advanced stage, i.e. Pre-Registration include, Zensun (Shanghai) Sci & Tech.

Find out more about the Chronic Heart Failure Pipeline Segmentation, Therapeutics Assessment, and Chronic Heart Failure Emerging Drugs @ Chronic Heart Failure Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Heart Failure Pipeline Report
• Coverage- Global
• Chronic Heart Failure Companies- Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, and others
• Chronic Heart Failure Pipeline Therapies- Ferinject (ferric carboxymaltose), Bisoprolol, LCZ696, Valsartan, Enalapril, Aliskiren, Vericiguat, Dapagliflozin, Normal saline (0.9%), nesiritide, furosemide, and others
• Chronic Heart Failure Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Chronic Heart Failure Pipeline Companies and Therapies, click here @ Chronic Heart Failure Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Heart Failure: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Heart Failure- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Neucardin: Zensun (Shanghai) Sci & Tech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Heart Failure Key Companies
21. Chronic Heart Failure Key Products
22. Chronic Heart Failure - Unmet Needs
23. Chronic Heart Failure - Market Drivers and Barriers
24. Chronic Heart Failure - Future Perspectives and Conclusion
25. Chronic Heart Failure Analyst Views
26. Chronic Heart Failure Key Companies
27. Appendix

Got Queries? Find out the related information on Chronic Heart Failure Mergers and acquisitions, Chronic Heart Failure Licensing Activities @ Chronic Heart Failure Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.